Camrelizumab plus chemotherapy combined with consolidative radiotherapy as first-line treatment for oligometastatic esophageal squamous cell carcinoma (ESCORT-1ST-RT): A single-arm, open-label, phase II trial

被引：0
|
作者：
Huang, W. [1 ]
Han, D. [1 ]
Li, B. [2 ]
Dong, J. [2 ]
机构：
[1] Shandong First Med Univ & Shandong Acad Med Sci, Shandong Canc Hosp & Inst, Jinan, Peoples R China
[2] Shandong First Med Univ, Radiotherapy Dept, Affiliated Canc Hosp, Jinan, Peoples R China
来源：
ANNALS OF ONCOLOGY | 2024年 / 35卷
关键词：
D O I：
10.1016/j.annonc.2024.08.1518
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1452P
引用
收藏
页码：S902 / S902
页数：1
相关论文
共 50 条
  • [31] Camrelizumab in combination with fluorouracil or taxol plus platinum chemotherapy as first-line treatment of esophageal squamous cell carcinoma: A multicenter, open-label, prospective cohort study.
    Zhao, Jun
    Hu, Wenqing
    Zhang, Xiaoling
    Du, Yunyi
    Yao, Chunmei
    Ma, Ning
    Yang, Wei
    Yang, Bo
    Xue, Yudong
    Gao, Yangjun
    Wang, Yu
    Liu, Min
    Wang, Mei
    Wang, Hui
    Feng, Tingting
    Cai, Linlin
    Zhang, Cuihua
    Ma, Kai
    Xu, Ning
    Lu, Jing
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16) : E16084 - E16084
  • [32] Update results of anlotinib combined with TQB2450 (PD-L1 blockade) as first-line treatment for advanced esophageal squamous cell carcinoma (ESCC): A single-arm, multicenter, open-label phase II clinical trial
    Hong, G.
    Meng, X.
    Yang, X.
    Zhang, Z. Y.
    Xia, J.
    Chen, Y-F.
    Wu, T.
    Shan, Z.
    Fan, Q.
    Wang, F.
    ANNALS OF ONCOLOGY, 2023, 34 : S861 - S861
  • [33] Toripalimab combined with bevacizumab and chemotherapy as first-line treatment for refractory, recurrent or metastatic cervical cancer: a single-arm, open-label, phase II TRIA
    Li, Chen
    Peng, Peng
    Yao, Hairong
    Liu, Dantong
    He, Yonglan
    Liu, Shikai
    Cheng, Ninghai
    Cao, Dongyan
    Xiang, Yang
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2023, 33 (SUPPL_4) : A38 - A38
  • [34] Toripalimab plus chemotherapy and radiotherapy for treatment-naive advanced esophageal squamous cell carcinoma: a single-arm phase 2 trial
    Wu, Lei
    Li, Baisen
    Wan, Gang
    Wang, Yi
    Zhu, Jie
    Liang, Long
    Leng, Xuefeng
    He, Wenwu
    Peng, Lin
    Han, Yongtao
    He, Shuya
    Wang, Dongsheng
    Zhou, Yehan
    Yi, Liang
    Zhang, Wencheng
    Pang, Qingsong
    Zhang, Wei
    Li, Tao
    Lang, Jinyi
    Liu, Yang
    Cao, Bangrong
    Wang, Qifeng
    NATURE COMMUNICATIONS, 2024, 15 (01)
  • [35] Camrelizumab plus apatinib for previously treated advanced adrenocortical carcinoma: A single-arm, open-label, phase 2 trial
    Wei, Zhigong
    Zhu, Yuchun
    Cai, Lei
    Peng, Xingchen
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [36] Apatinib plus camrelizumab in patients with advanced cervical cancer: A multicentre, open-label, single-arm, phase II trial
    Huang, X.
    Shen, J.
    Xiong, Y.
    Wang, Y.
    Cao, X.
    He, M.
    Zou, G.
    Deng, Y.
    Wang, X.
    Lan, C.
    GYNECOLOGIC ONCOLOGY, 2020, 159 : 43 - 43
  • [37] Camrelizumab Plus Apatinib in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma: An Open-Label, Single-Arm, Phase II Study
    Ding, Xi
    Zhang, Wei-Jing
    You, Rui
    Zou, Xiong
    Wang, Zhi-Qiang
    Ouyang, Yan-Feng
    Peng, Lan
    Liu, You-Ping
    Duan, Chong-Yang
    Yang, Qi
    Lin, Chao
    Xie, Yu-Long
    Chen, Si-Yuan
    Liu, Yong-Long
    Gu, Chen-Mei
    Xie, Ruo-Qi
    Huang, Pei-Yu
    Hong, Ming-Huang
    Hua, Yi-Jun
    Chen, Ming-Yuan
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (14) : 2571 - +
  • [38] Efficacy and safety of camrelizumab combined with chemotherapy in the first-line treatment of advanced gastric cancer: a single-arm, phase II study
    Liu, Wenlou
    Wang, Hongmei
    Zhao, Yang
    Ge, Yan
    Tang, Juangjuang
    Cao, Menghan
    Matsas, Silvio
    Breadner, Daniel Adam
    Qin, Xiaobing
    Han, Zhengxiang
    JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2024, 15 (04)
  • [39] Anlotinib combined with nab-paclitaxel and cisplatin as neoadjuvant treatment for esophageal squamous cell carcinoma (ESCC): A single-arm, open-label phase II clinical trial.
    Zhang, Yan-Feng
    Hao, An-Lin
    Hong, Yong-Gui
    Li, Xiao-Ming
    Liang, Wei-Min
    Zheng, Zhi-Xin
    Yang, Guang-Yi
    Guo, Xiao-Feng
    Wen, Yan-Yan
    Cao, Heng
    Le, Cheng
    Song, Hua-Jie
    Su, Wen-Zhong
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16) : E16015 - E16015
  • [40] Update results of paclitaxel and cisplatin in combination with anlotinib as first-line regimen for advanced esophageal squamous cell carcinoma (ESCC): A multicenter, single-arm, open-label phase II clinical trial.
    Wang Junsheng
    Luo Suxia
    Li Ning
    Wu Tao
    Hong Yonggui
    Guo Yanzhen
    Cheng Yufeng
    Li Baosheng
    Tan Bingxu
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (03)
12345